

February 28 – March 2, 2018, Washington, DC

### The Ritz-Carlton Hotel, 1150 22<sup>nd</sup> Street NW

Wifi Network: RitzCarlton\_CONFERENCE Password: MRA2018

Wednesday, February 28 <sup>th</sup>		
1:30-5:30 pm	Melanoma Advocates & Foundations Forum (invitation only)Salon II	
4:00-8:00 pm	Registration openFoyer of Salon III	
6:00-7:30 pm	Opening Reception Salon III	
Thursday, March 1 <sup>st</sup>		
6:30 am-6:00 pm	RegistrationOutside of Salon Ballroom	
7:00-8:15 am	General BreakfastSalon III	
7:00-8:15 am	Young Investigators Breakfast (by invitation only)Plaza Ballroom	
8:30-8:45 am	Opening Remarks Day 1	
8:45-9:15 am	Lecture Suzanne Topalian, Johns Hopkins University: A decade of progress in melanoma	
9:15-11:10 am	Session 1: New approaches and tools for predicting efficacy: immunotherapy and beyond Chair: Jennifer Wargo	
9:15-9:40	Kai Wucherpfennig, Dana-Farber Cancer Institute: Human anti-MICA monoclonal antibodies for melanoma immunotherapy	
9:40-10:05	Marisol Soengas, Spanish National Cancer Research Center (CNIO): Imaging and targeting dormant and pro-metastatic melanoma lesions in vivo	
10:05-10:25	Iwei Yeh, University of California, San Francisco: Activating ß-catenin mutations cooperate with BRAFV600E to promote invasion	
10:25-10:45 am	Break	
10:45-11:10	<b>Yvonne Saenger, Columbia University</b> : Combination immunotherapy leads to decreased tumor growth, improved survival and intratumoral immune infiltration in transgenic murine model of melanoma	



February 28 – March 2, 2018, Washington, DC

11:10 am-12:00 pm	Session 2: Microbial influences on immunotherapy efficacy Chair: Marisol Soengas	
11:10-11:35	Tom Gajewski, University of Chicago: The commensal microbiota as a new variable	
11:35-12:00	impacting cancer immunotherapy  Jennifer Wargo, MD Anderson Cancer Center: Profiling the microbiome to predict immunotherapy efficacy	
12:00-12:10 pm	Transition to lunch	
12:10-1:15 pm	Lunch and Panel Discussion	
1:15-1:30 pm	Transition to room	
1:30-3:00 pm	Session 3: Melanoma metastasis	
1:30-1:55	Michael Davies, MD Anderson Cancer Center: Targeting BRAF mutant brain metastases	
1:55-2:15	Manuel Valiente, Spanish National Cancer Research Center (CNIO): Blocking brain metastasis by targeting the microenvironment	
2:15-2:35	Lucia Jilaveanu, Yale University: Response to PD-1 inhibitors in melanoma patients with brain metastases	
2:35-3:00	<b>Robert Vonderheide, University of Pennsylvania</b> : Radiation and immune checkpoint blockade from mechanism to patients	
3:00-3:20 pm	Break	
3:20-5:00 pm	Session 4: New targets for melanomaSalon I & II Chair: Ido Amit	
3:20-3:45	<b>F. Stephen Hodi, Dana-Farber Cancer Institute</b> : Combined CTLA-4 and angiopoietin-2 blockade in advanced melanoma patients	
3:45-4:05	Niroshana Anandasabapathy, Weill Cornell Medical School: Tissue immune differentiation reveals new pathways of melanoma escape	
4:05-4:30	Michal Lotem, Hadassah Medical Organization: Mechanism of action of SLAMF6 and its potential role in immunotherapy	



February 28 – March 2, 2018, Washington, DC

4:30-4:55	Ido Amit, Weizmann Institute of Science: Sing	gle cell analysis and perturbation of the
	tumor-immune ecosystem	
4:55-5:00	Closing Remarks Day 1	
	Kristen Mueller, MRA Scientific Program Direc	tor
	,	
6:30-9:00 pm	Reception and Dinner	Teddy & the Bully Bar*
6:30-9:00 pm	Reception and Dinner  Dress: Casual	<b>Teddy &amp; the Bully Bar*</b> 1200 19th Street, NW, (202) 872-8700

<sup>\*6:15-7:00</sup> pm: Transportation provided to Teddy & Bully Bar; Shuttles will depart from the circular drive outside the hotel lobby. Upon exiting the hotel, bear to your right and shuttles will be stationed in the breezeway between the hotel and art gallery on the property.

# Friday, March 2<sup>nd</sup>

6:30-10:00 am	Registration open	Outside Salon Ballroom
7:00-8:30 am	General Breakfast	Salon III
7:00-8:30 am	Industry Roundtable Breakfast (by invitation only)	Plaza Ballroom
8:40-8:45 am	Opening Remarks Day 2 Kristen Mueller, MRA Scientific Program Director	Salon I & II
8:45-11:25 am	Session 5: New strategies in preventing and treating mela Chair: Lewis Cantley	inoma
8:45-9:10	Georgina Long, Melanoma Institute Australia, University of for melanoma	of Sydney: Adjuvant therapy
9:10-9:30	<b>Steve Barthel, Brigham and Women's Hospital</b> : Melanoma unexpected variable in cancer immunotherapy?	a cell-intrinsic Tim-3: An
9:30-9:50	Amanda Lund, Oregon Health & Science University: Lymp inflammation in melanoma	hatic vessels and T cell-
9:50-10:15	<b>Boris Bastian, University of California, San Francisco:</b> Stru-BRAF fusion kinases affect drug response	cture and expression level of
10:15-10:35 am	Break	
10:35-11:00	<b>Susan Swetter, Stanford University</b> : Artificial intelligence (detection	(AI) for cutaneous melanoma
11:00-11:25	Emily Bernstein, Icahn School of Medicine at Mount Sinai for melanoma oncogene discovery	: Harnessing the epigenome
11:25-11:55	<b>Lecture Lewis Cantley, Weill Cornell Medical School</b> : Development treatment of melanoma	t of AMPK activators for



February 28 - March 2, 2018, Washington, DC

A decade of MRA: Funding for the future
Moderator: Margaret Anderson, MRA Board of Directors
Panelist: Debra Black, MRA Board Chair and Co-founder
Panelist: Georgina Long, Melanoma Institute Australia, University

of Sydney

Panelist: Richard Marais, Cancer Research UK Manchester Institute

Panelist: Suzanne Topalian, Johns Hopkins University, MRA Board of Directors

Panelist: Jedd Wolchok, Memorial Sloan Kettering Cancer Center

**Closing Remarks** 12:35-12:45 pm

11:55-12:35 pm Panel Discussion

Michael Kaplan, MRA President and CEO Louise Perkins, MRA Chief Science Officer

12:45-2:00 pm Lunch and Departures.....Salon III